Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Merck
Queensland Health
Mallinckrodt
Fuji
Boehringer Ingelheim
Cerilliant
Chinese Patent Office
AstraZeneca

Generated: April 26, 2018

DrugPatentWatch Database Preview

NUVESSA Drug Profile

« Back to Dashboard

Which patents cover Nuvessa, and when can generic versions of Nuvessa launch?

Nuvessa is a drug marketed by Chemo Research Sl and is included in one NDA. There are five patents protecting this drug.

This drug has fourteen patent family members in nine countries.

The generic ingredient in NUVESSA is metronidazole. There are eighteen drug master file entries for this compound. Eighty-five suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
Summary for NUVESSA
International Patents:14
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 3
Bulk Api Vendors: 125
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NUVESSA at DailyMed
Drug patent expirations by year for NUVESSA
Pharmacology for NUVESSA
Medical Subject Heading (MeSH) Categories for NUVESSA

US Patents and Regulatory Information for NUVESSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for NUVESSA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021 Belgium ➤ Sign Up PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Harvard Business School
Fuji
Colorcon
Teva
US Army
AstraZeneca
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.